Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103571 · ClinicalTrials.gov registry record · Phase 4
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
A Phase 4 study of Schizophrenia, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 5
- Study locations
NCT00103571 is a Phase 4 study of Schizophrenia that has completed, run by Eli Lilly and Company. The registered enrollment target is 600 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (176% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT00103571, a Phase 4 study of Schizophrenia, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Conditions Studied
Interventions
- DRUG Olanzapine
- DRUG Aripiprazole
Study Locations (5)
Ohio
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Beachwood
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Canton
Missouri
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Saint Charles
Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Memphis
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Rio Piedras
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103571
The ClinicalTrials.gov registry entry for NCT00103571 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (176% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine is the first listed.
NCT00103571 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Missouri, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00103571 about?
NCT00103571 is a clinical study titled "Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia". The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
What is the current status of trial NCT00103571?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2004-07. Estimated completion is 2006-08.
What conditions does trial NCT00103571 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00103571?
The interventions under investigation include: Olanzapine (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00103571?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00103571 being conducted?
This trial has 5 study locations across Missouri, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.